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CC BY-NC-ND license (http://creativeAbstract Mutations in the KRAS oncogene represent one of the most prevalent genetic alter-
ations in colorectal cancer (CRC), the third leading cause of cancer-related death in the US. In
addition to their well-characterized function in driving tumor progression, KRAS mutations
have been recognized as a critical determinant of the therapeutic response of CRC. Recent
studies demonstrate that KRAS-mutant tumors are intrinsically insensitive to clinically-used
epidermal growth factor receptor (EGFR) targeting antibodies, including cetuximab and pani-
tumumab. Acquired resistance to the anti-EGFR therapy was found to be associated with
enrichment of KRAS-mutant tumor cells. However, the underlying molecular mechanism of
mutant-KRAS-mediated therapeutic resistance has remained unclear. Despite intensive ef-
forts, directly targeting mutant KRAS has been largely unsuccessful. This review summarizes
the recent advances in understanding the biological function of KRAS mutations in determining
the therapeutic response of CRC, highlighting several recently developed agents and strategies
for targeting mutant KRAS, such as synthetic lethal interactions.
Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).Introduction
Despite recent advances in early detection and therapeutic
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commons.org/licenses/by-nc-nd/most deadly cancers in the United States.1 It is estimated
that nearly 137,000 people will be diagnosed, and 50,000
will die from the disease in 2014.2 While surgical removal
leads to high cure rates of localized disease, metastatic
CRCs are typically associated with a poor prognosis with the
majority of patients dying within two years upon diagnosis,
resulting in a five-year survival rate of just 11%.3,4
Colorectal tumorigenesis often begins with precursor
lesions in the colonic epithelium, and is driven by a series of
genetic and epigenetic alterations.5,6 One of the earliest
genetic changes is the loss of the APC tumor suppressor
gene, which antagonizes b-catenin signaling and is mutatedand hosting by Elsevier B.V. This is an open access article under the
3.0/).
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activation of the oncogene KRAS, which is mutated in over
one-third of CRCs.5,8 Genetic instability has also been
implicated to contribute to colorectal tumorigenesis.9,10
KRAS mutations, although not a significant prognostic fac-
tor, have been shown to play a critical role in CRC treat-
ment. Over the years, activation of this oncogene has been
linked to resistance to the agents utilized in front-line
therapy for CRC.11,12 Intensive efforts have been devoted
to understanding how KRAS mutations affect CRC therapy,
in particular targeted therapy, and how to overcome
mutant-KRAS-mediated therapeutic resistance. The Na-
tional Cancer Institute (NCI) has recently established the
RAS Program to explore innovative ways to attack the
proteins encoded by mutant RAS genes or other vulnera-
bilities as a way to treat key types of cancer such as CRC. In
this review, we summarize the current understanding of
KRAS biology and how the mutational status of KRAS affects
the response to CRC therapy, as well as recent advances in
developing novel therapeutic strategies and agents for
targeting KRAS-mutant cancers.KRAS biology
RAS proteins represent prototypical members of a large
family of small GTP-binding proteins.13 The human RAS su-
perfamily consists of more than 100 members, which can be
divided into six subfamilies.14 Three prototypical RAS pro-
teins include HRAS, NRAS, and KRAS.15 While they are highly
homologous in amino acid sequence and ubiquitously
expressed, KRAS is the only one that is essential for normal
development as shown by mouse genetic studies.16e18 KRAS
can be expressed as two different splice variants, referred to
as 4Aand4B, through alternative splicingwithinexon 4.15 The
4B variant is the dominant form commonly known as KRAS.8
KRAS is a membrane-bound GTPase that cycles between
an active GTP-bound form and an inactive GDP-bound form
due to the hydrolysis of the bound GTP (Fig. 1A).14,19 The
switches between these two states are controlled by two
classes of proteins: guanosine nucleotide exchange factors
(known as GEFs) and GTPase-activating proteins (known as
GAPs). As their names suggest, GEFs assist with the ex-
change of bound GDP with GTP, whereas GAPs stimulate the
hydrolytic ability of RAS to convert bound GTP to GDP.13
The proper membrane localization and function of the
RAS proteins are regulated by several post-translational
modifications in the C-terminal “CAAX” motif, including
farnesylation of the cysteine residue, proteolytic removal
of the terminal three residues (AAX), as well as methylation
of the cysteine residue.15,19 In addition, the plasma mem-
brane localization of KRAS also requires a basic poly-lysine
region located immediately upstream of the C-
terminus.19,20
Once properly localized, KRAS mediates a myriad of
intracellular signaling events through its numerous effector
pathways. Signaling by receptor tyrosine kinases (RTKs), in
particular the epidermal growth factor receptor (EGFR), is
a widely-utilized and well-understood model for studying
KRAS activation (Fig. 1A).16,21 The activation of EGFR upon
ligand binding and its subsequent auto-phosphorylation
create a docking site for the adaptor protein growth-factor-receptor-bound protein 2 (GRB2), which binds to
the GEF Son of Sevenless (SOS) in the cytosol. The
recruitment of this protein complex to the phosphorylated
receptor enables SOS to function as the exchange factor for
KRAS, resulting in nucleotide exchange and the GTP-bound
form of KRAS (Fig. 1A).16,21,22
Among numerous downstream effectors of KRAS, the
best characterized include RAF and phosphoinositide-3 ki-
nase (PI3K), as well as the GEFs for the RAS-like (Ral) small
GTPases (RalGEFs).23,24 The major axes of RAS signaling
through the RAF/MEK/ERK and PI3K/AKT cascades ulti-
mately control processes such as cell growth and survival
(Fig. 1A).16 This is accomplished in part by ERK-regulated
activation of transcription factors that promote cell cycle
progression, and by AKT-mediated inactivation of pro-
apoptotic proteins for apoptosis suppression.16,25 In addi-
tion, a number of alternate effectors of KRAS have been
described in an extensive body of literature, which regulate
processes such as cell migration, endocytosis, changes in
cytoskeleton, and calcium signaling.19,23,25,26
KRAS mutations and role in CRC
Nearly 30% of human cancers possess activating RAS muta-
tions,27 85% of which are KRAS mutations.28 In CRCs, KRAS
mutations are found in approximately 35%e40% of cases, and
those ofHRAS andNRAS in<5%.4,29 The vastmajority of KRAS
mutations are located in codons 12 and 13, and the
remainder in codons 61, 146, and other residues.29,30 While
the hotspot codon 12 and 13 mutations of KRAS do not
interfere with its ability to associate with GAPs, they alter
the position of a catalytic glutamate residue at codon 61.13,15
This results in the reduced GTPase activity of KRAS and
decreased rate of GTP hydrolysis by 3e9 fold compared to
wild-type (WT) KRAS.15 Using isogenic knock-out and knock-
in CRC cell lineswith eitherWT KRAS or activatingmutations,
recent studies have illustrated that these mutations play a
significant role in tumor cell survival and tumor pro-
gression.31e34 The functional consequences of KRAS muta-
tions include increased cellular proliferation, suppression of
apoptosis, altered cellmetabolism, and changes in the tumor
microenvironment.13,27 For example, GTP-bound KRAS en-
ables the upregulation of growth factors and transcription
factors known to promote cell cycle progression, such as c-
JUN and c-FOS.13 Recent studies identified the Yes-
associated protein 1 (YAP1) transcriptional co-activator as
a key mediator of the oncogenic effect of KRAS.35,36 From a
therapeutic standpoint, suppression of apoptosis is probably
one of the most important consequences of KRAS muta-
tions.27 Activated KRAS can inhibit the apoptotic signaling
cascade through its effector PI3K, which in turn activates
AKT,25,27 a potent pro-survival kinase that inhibits apoptosis
via several mechanisms, such as the phosphorylation and
subsequent inactivation of the pro-apoptotic Bcl-2 family
protein BAD, and the inhibitory phosphorylation of the
initiator caspase-9.25
Current treatments and targeted therapy
CRC patients are often treated with conventional cytotoxic
chemotherapy and recently developed targeted therapy.
Figure 1 EGFR-induced and KRAS-mediated signaling pathways. (A) Activation of EGFR upon ligand binding and its subsequent
auto-phosphorylation create a docking site for the SOS/GRB2 complex, resulting in nucleotide exchange by SOS and the GTP-bound
form of KRAS. KRAS then signals through the RAF/MEK/ERK and PI3K/AKT cascades to promote cell growth and suppress apoptosis.
(B) Anti-EGFR antibodies, including cetuximab and panitumumab, bind to EGFR and prevent ligand binding and subsequent KRAS
activation, leading to growth suppression and cell death due to the inhibition of the RAF/MEK/ERK and PI3K/AKT pathways. Mutant
KRAS can override the effect of anti-EGFR antibodies leading to cell growth and survival.
6 K. Knickelbein, L. ZhangCytotoxic chemotherapy typically entails the use of py-
rimidine analogs such as 5-fluorouracil (5-FU),37 which in-
hibits thymidylate synthase required for nucleotide
synthesis.38 Other cytotoxic drugs commonly used for CRC
treatment include the topoisomerase I inhibitor irinotecan,
the platinum drug oxaliplatin, and the oral pro-drug cape-
citabine (metabolized into fluorouracil).38,39 Front-line
treatment involves combinations of these agents, such as
FOLFOX (fluorouracil, leucovorin, and oxaliplatin) and
FOLFIRI (fluorouracil, leucovorin, and irinotecan),12,38which have been shown to improve response rates and
overall survival of CRC patients over single agents.39
Targeted therapy, referred to as treatments that aim to
inhibit the processes that cancer cells rely on for survival
and proliferation, has recently moved to the forefront of
CRC treatment.40 Several targeted drugs have been
approved by the US Food and Drug Administration (FDA) for
CRC treatment, including the anti-vascular endothelial
growth factor (VEGF) antibody bevacizumab, which sup-
presses tumor angiogenesis, the anti-EGFR antibodies
Mutant KRAS in colorectal cancer 7cetuximab and panitumumab, and more recently, the
multi-kinase inhibitor regorafenib, which targets RTKs
involved in angiogenesis and mitogenic signaling.41,42 The
utilization of targeted therapy has increased significantly.
For example, it was estimated that roughly 44% of all CRC
patients treated in the US received anti-EGFR antibody
therapy in 2008.43
EGFR is a member of the ERBB family of RTKs that is
frequently overexpressed in CRC.44 Much akin to KRAS
signaling, EGFR transduces signals from extracellular stim-
uli through key intracellular pathways, such as the RAS/
RAF/MEK/ERK and PI3K/AKT cascades.45 The anti-EGFR
antibodies used for CRC treatment, including cetuximab
and panitumumab, both can inhibit ligand binding and EGFR
homo-dimerization or hetero-dimerization with other ERBB
family members (Fig. 1B), which are necessary for its sub-
sequent auto-phosphorylation and full activation.42,46
Cetuximab is a chimeric human-murine antibody of the
IgG1 isotype, and panitumumab is a humanized antibody of
the IgG2 isotype.47,48 In addition to their effect on ligand
binding, cetuximab and panitumumab can promote EGFR
internalization and subsequent degradation, thus
decreasing the cell surface level of EGFR.48 Interestingly,
cetuximab can also block EGFR nuclear translocation
whereby it can act as a transcription factor.42 Both cetux-
imab and panitumumab have become part of first-, second-
, and third-line therapy for CRC.12,48,49 Data from clinical
trials have shown the therapeutic benefit of anti-EGFR
antibody therapy either as a stand-alone agent or in com-
bination with chemotherapy regimens.50e53 However, pri-
mary and secondary resistance to this therapy has become
a significant issue.Alterations of KRAS status and the response to
targeted therapy
A major challenge in anti-cancer therapy, especially tar-
geted therapy, is the emergence of drug resistance. This
has been exemplified by the finding that alterations in the
KRAS gene render anti-EGFR antibodies ineffective for CRC
treatment. An initial study published in 2006 showed the
lack of response to cetuximab in patients with KRAS-mutant
metastatic CRCs,54 followed by another study confirming
the causal role of KRAS mutations.55 A host of subsequent
studies, including further clinical trials and retrospective
analyses of tumor samples, verified the notion that KRAS
mutations underlie the lack of response to anti-EGFR
therapy.56e59 These findings led to the issuance of a pro-
visional clinical opinion by the American Society of Clinical
Oncology in 2009, stating that metastatic CRC patients
eligible to receive an anti-EGFR antibody therapy should
have their KRAS mutational status profiled; and those with
a codon 12 or 13 mutation in KRAS should be excluded from
this treatment.60 Collectively, these studies have estab-
lished the KRAS status as a key factor in choosing treatment
options of metastatic CRC patients, as well as a major
biomarker of resistance to anti-EGFR antibody therapy.61
A critical question that remains is how resistance to anti-
EGFR therapy emerges. Several recent studies have char-
acterized the mechanism of secondary resistance to anti-
EGFR therapy by assessing the temporal alterations of KRASmutational status. Cell culture studies using CRC cells that
are exquisitely sensitive to anti-EGFR antibodies have
shown that prolonged treatment with anti-EGFR antibodies
selects for resistant clones that harbor KRASmutations.62,63
The results of these studies suggest that KRAS mutations
can pre-exist in a small proportion of a population of cancer
cells, and can also be continuously generated de novo due
to genomic instability. Thus, the pressure of anti-EGFR
treatment enriches cell populations harboring KRAS muta-
tions, resulting in acquired resistance to the treatment.64
Further supporting their role in mediating resistance to
anti-EGFR therapy, KRAS mutations were detected in serum
samples and metastases from treated patients, with the
levels of these mutations correlated with relapse and dis-
ease progression.63,65,66 In addition to point mutations,
frank amplification of KRAS, although an extremely rare
event in CRC, can also lead to resistance to anti-EGFR
therapy.67
The molecular mechanisms by which KRAS mutations
lead to resistance to anti-EGFR therapy have remained
unresolved. Given the role of KRAS as a key downstream
effector of EGFR signaling, it is perhaps not surprising that
constitutive activation of KRAS by mutations bypasses the
upstream effect of EGFR inhibition. However, players that
are responsible for circumventing the response to anti-
EGFR therapy in a KRAS-mutant background remain
elusive.68 Recent studies indicate that KRAS-mutant cells
heavily rely on the RAF/MEK/ERK cascade for survival,
which provides a clue for dissecting the precise signaling
pathways underlying the resistance phenotype.62 Analysis
of cell line models and CRC samples indicates that onco-
genic KRAS plays a role in the maintenance of high
expression levels of Bcl-XL, an anti-apoptotic Bcl-2 family
protein, whose overexpression alone is sufficient to confer
resistance to anti-EGFR antibodies in CRC cells.69 This study
suggests that suppression of apoptosis is a mechanism of
mutant-KRAS-mediated resistance to anti-EGFR therapy.Targeting mutant KRAS for anti-cancer therapy
The high mutation frequency and its role in therapeutic
resistance make KRAS an ideal target for anti-cancer ther-
apy. The proof-of-principle for targeting KRAS has been
demonstrated by the profound phenotypes of KRAS ablation
in mice and human cancer cells.45,70 A variety of strategies
have been designed to target mutant KRAS, including direct
targeting by inhibiting its GTPase activity and indirect tar-
geting by suppressing its post-translational modifications or
downstream effectors (Table 1).84
Despite numerous attempts, developing small-molecule
inhibitors of KRAS has proven to be extremely challenging.
Several recent reports have described novel small mole-
cules that interfere with GEF binding to lock KRAS in an
inactive state.85 For example, in silico and NMR-based
screens were used to identify small molecules that bind
to a distinct pocket on KRAS and inhibit SOS-mediated
nucleotide exchange to prevent the activation of WT or
mutant KRAS.52,71,72 More specific approaches have been
utilized to identify small-molecule inhibitors that cova-
lently bind to mutant KRAS. A disulphide-fragment-based
screening approach was used to identify electrophilic
Table 1 Recently developed agents for targeting mutant KRAS.
Target Mechanism of action References
Direct targeting agents
Small molecules from fragment-based
screen
KRAS; WT, G12V, G12D; HRAS Inhibition of SOS binding 71
4,6-dichloro-2-methyl-3-aminoethyl-
indole (DCAI)
KRAS; G12D Inhibition of SOS binding 72
Hits from fragment-based screen KRAS; G12C Inhibition of SOS binding 73
SML-8-73-1 KRAS; G12C GDP analog 74
Indirect targeting agents
Farnesyltransferase inhibitors Farnesyltransferase; post-translational
modification
Inhibition of prenylation
by farnesyl group
75,76
Geranylgeranyltransferase I inhibitors Geranylgeranyltransferase I;
post-translational modification
Inhibition of prenylation
by geranylgeranyl group
77
Inhibitors of KRAS and PDEd interaction KRAS and PDEd interaction Inhibition of prenylation 78
Inhibitors of RAF, MEK, and PI3K RAF, MEK, and PI3K Inhibition of KRAS effector
pathways
41,79,80
Cetuximab and Pimasertib EGFR and MEK; upstream and downstream
KRAS pathway components
Dual inhibition of EGFR
and MEK signaling
62
NVP-BEZ235-AN and AZD6244 PI3K and MEK; upstream and downstream
KRAS pathway components
Dual inhibition of PI3K
and MEK signaling
81
siRNA Human and mouse KRAS pathway genes Inhibition of protein
expression
82
RAF265 and Selumetinib RAF1/BRAF and MEK Dual inhibition of RAF and
MEK signaling
83
Figure 2 Mutant-KRAS-mediated synthetic lethality. While a
mutation in KRAS or gene X alone is insufficient to kill cells, a
combination of mutations in these two genes can lead to cell
death, resulting in synthetic lethality. Therefore, specific tar-
geting of mutant KRAS can be achieved indirectly by targeting
gene X.
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residue in the G12C mutant of KRAS.73 While these com-
pounds do not affect WT KRAS, they can preferentially bind
the G12C mutant, disrupt SOS binding, and increase its af-
finity for GDP to prevent the activation of mutant KRAS. A
similar approach identified a GDP analog as a covalent in-
hibitor of the G12C mutant.74
Another approach for targeting KRAS is to inhibit its
post-translational modifications using farnesyltransferase
(FTase) inhibitors (FTIs), which inhibit the prenylation of
KRAS that is required for proper plasma membrane
attachment.75 FTIs were shown to suppress cancer cell
growth in pre-clinical studies, but unfortunately, they did
not exhibit clinical efficacy as single agents.77,86 The lack of
clinical response to FTIs was explained by the prenylation
of KRAS through alternative mechanisms, such as those
involving geranylgeranyltransferase I (GGTase I).76,77 Dual
inhibitors of GGTase and FTase, such as L778,123, were
therefore developed. However, its toxicities in clinical tri-
als prohibited further clinical development.87 Another
strategy illustrated by a recent study is to inhibit the
interaction between KRAS and cyclic GMP phosphodies-
terase d (PDEd), which mediates correct localization and
signaling by farnesylated KRAS.78
Targeting KRAS-mutant cancer can also be achieved by
inhibiting other components of its key signaling axes or
through combination therapies. For example, the RAF in-
hibitor regorafenib has been recently approved by the FDA
for the treatment of metastatic CRCs.41 A number of PI3K
and MEK pathway inhibitors have been developed and
tested in clinical trials.79,80 A small interfering RNA (siRNA)
library against RAS pathway genes has also been created,
and transfection of this library into CRC cells could suppress
cell growth both in vitro and in vivo.82 Utilizing CRC celllines that were selected for resistance to anti-EGFR anti-
bodies, a recent study revealed that dual inhibition of both
EGFR and MEK resulted in a pronounced reduction of cell
viability.62 Concomitant blockade of RAF1 and MEK in CRC
cells with activating KRAS mutations was also shown to
drastically reduce cell viability.83 Furthermore, the
Table 2 Synthetic lethal interactions in KRAS-mutant cancers.
Genes or proteins Cancer types Methods of discovery References
PLK1 Colorectal shRNA screen 92
Anaphase-Promoting
Complex/Cyclosome (APC/C)
Colorectal shRNA screen 92
Proteasome Colorectal shRNA screen 92
TBK1 Lung shRNA screen 93
STK33 Colorectal, breast,
and leukemia
shRNA screen 94
SNAIL Colorectal shRNA screen 95
TAK1 Colorectal Gene expression profiling
and knockdown
96
GATA2 Lung shRNA screen 97
Bcl-XL/MEK Colorectal, pancreatic,
and lung
shRNA screen 98
Mutant KRAS in colorectal cancer 9combination of PI3K and MEK inhibitors suppressed murine
lung tumors with the G12D mutant KRAS.81
Despite the promises, targeting KRAS-driven cancers
remains one of the most difficult challenges in anti-cancer
therapy due to several obstacles, including limited under-
standing of RAS-mediated signaling transduction feedback
loops, pathway redundancy, tumor heterogeneity, unclear
mechanisms of how RAS proteins activate their downstream
targets, as well as unresolved structures of protein com-
plexes formed by RAS oncoproteins.88 It is essential to fill in
these knowledge gaps in order to develop more effective
agents for targeting KRAS-mutant cancers.
Synthetic lethality of KRAS mutations
An emerging theme for targeting oncogenic mutations,
including those of KRAS, exploits the concept of synthetic
lethality, a genetic term referring to loss of viability
resulting from a combination of two separate non-lethal
mutations.89 While synthetic lethality has been exten-
sively studied in lower organisms such as yeast, its appli-
cations have only recently been extended into anti-cancer
therapy. In the case of mutant KRAS, synthetic lethality has
been used loosely to indicate selective killing of KRAS-
mutant cells as the result of another mutation, treatment
with a pharmacological agent, a change in gene expression,
or other perturbations (Fig. 2). Another good example is the
sensitivity of BRCA1- or BRCA2-mutant breast tumors to
poly (ADP-ribose) polymerase (PARP) inhibitors.90 It is
attractive to use this approach to target oncogenic muta-
tions because pharmacologically more tractable targets can
be explored to develop more efficacious small-molecule
inhibitors.
A powerful approach for uncovering synthetic lethal in-
teractions is large-scale screening based on RNA interfer-
ence (RNAi).91 For KRAS-mutant cancers, a host of synthetic
lethal interactions have been uncovered and characterized
(Table 2). A recent study employing a small hairpin RNA
(shRNA) library screen on isogenic WT and KRAS-mutant CRC
cells identified several synthetic lethal interactions with
mutant KRAS, including depletions of the mitotic protein
polo-like kinase-1 (PLK1), anaphase-promoting complex/cyclosome (APC/C) subunits, as well as components of the
proteasome.92 An RNAi-based screen was also used to
identify the depletion of TANK-binding kinase 1 (TBK1), a
kinase involved in NF-kB signaling, to be synthetically lethal
with mutant KRAS.93 This finding also provided a mecha-
nistic link between suppression of TBK1 expression with the
downregulation of Bcl-XL through NF-kB signaling.
93 Other
synthetic lethal partners with mutant KRAS include the
transforming growth factor beta-activated kinase 1 (TAK1),
the Snail2 transcriptional repressor, the serine/threonine
protein kinase STK33, the GATA2 transcription factor, and
the dual inhibition of Bcl-XL and MEK.
94e98 These examples
illustrate the usefulness of genetic approaches for uncov-
ering novel synthetic lethal interactions, which can
potentially be translated into new therapeutic agents to
selectively target KRAS-mutant cancers.Conclusions
KRAS mutations are not only one of the most frequent ge-
netic alterations in CRC, but also a critical determinant of
response to EGFR-targeted therapy. A better understanding
of how the KRAS oncoprotein activates its downstream
targets, coupled with targeting mutant KRAS using novel
agents and approaches, such as synthetic lethal in-
teractions, may afford new ways of curing KRAS-driven
cancers including CRC.Conflicts of interest
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